Meeting
2016 Gastrointestinal Cancers Symposium
Randomized phase II trial of prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in CapeOX for stage II/III colon cancer patients (YCOG1205).
Authors
Jun Watanabe
Yokosuka Kyosai Hospital, Yokosuka, Japan
Jun Watanabe , Mitsuyoshi Ota , Kazuteru Watanabe , Shuuji Saito , Koutaro Nagamine , Yusuke Suwa , Hirokazu Suwa , Masashi Momiyama , Atsushi Ishibe , Yasushi Ichikawa , Mari Saito Oba , Itaru Endo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000008814
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 703)
DOI
10.1200/jco.2016.34.4_suppl.703
Abstract #
703
Poster Bd #
K22
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy.
First Author: Teppei Yamada
Poster
2024 ASCO Annual Meeting
Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.
First Author: Ingrid A. Franken
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701).
First Author: Shunji Endo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai